Psychosocial functioning in schizophrenia: Are some symptoms or demographic characteristics predictors across the functioning domains?

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 2471-2477

  Suttajit, Sirijit ^a   Arunpongpaisal, Suwanna ^b   Srisurapanont, Manit ^a   Thavichachart, Nuntika ^c   Kongsakon, Ronnachai ^d   Chantakarn, Sunanta ^e   Chantarasak, Vasu ^f   Jariyavilas, Apichat ^g   Jaroensook, Piyadit ^h   Kittiwattanagul, Khanogwan ⁱ   Nerapusee, Osot ^j  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

^f Somdet Chaopraya Institute of Psychiatry   (Thailand)

^g Srithanya Hospital   (Thailand)

^h Prasrimahabhodhi Psychiatric Hospital   (Thailand)

ⁱ Khon Kaen Rajanagarindra Psychiatric Hospital   (Thailand)

^j Janssen Cilag Bangkok   (Thailand)

more..

Author keywords

Age; Association; Correlation; Excitement; Hostility; Negative symptoms; Severity

Indexed keywords

ADULT; AGE; ANXIETY DISORDER; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DEPRESSION; DISEASE SEVERITY; EXCITEMENT; FEMALE; FUNCTIONAL STATUS ASSESSMENT; HOSTILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; NEGATIVE SYNDROME; ONSET AGE; PERSONAL AND SOCIAL PERFORMANCE SCALE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; STEPWISE MULTIPLE LINEAR REGRESSION ANALYSIS; THOUGHT DISORDER;

EID: 84943188260     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S88085     Document Type: Article

References (49)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington (VA): American Psychiatric Association; 2013.
2. Juckel G, Morosini PL. The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Curr Opin Psychiatry. 2008;21(6):630-639.
3. Nasrallah HA, Targum SD, Tandon R, McCombs JS, Ross R. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv. 2005;56(3):273-282.
4. Suzuki T, Remington G, Mulsant BH, et al. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 2012;197(1-2):1-6.
5. Mueser KT. Cognitive functioning, social adjustment and long term outcome in schizophrenia. In: Sharma V, Harvey P, editors. Cognition in Schizophrenia: Impairments, Importance and Treatment Strategies. New York: Oxford University Press; 2000:157-177.
6. Meltzer HY, Bobo WV, Roy A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2008;69(2):274-285.
7. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64(5):361-368.
8. Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol. 2010;13(4):451-460.
9. Haro JM, Novick D, Suarez D, Ochoa S, Roca M. Predictors of the course of illness in outpatients with schizophrenia: a prospective three year study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1287-1292.
10. Schennach-Wolff R, Jager M, Seemuller F, et al. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr Res. 2009;113(2-3):210-217.
11. Puig O, Penades R, Gasto C, Catalan R, Torres A, Salamero M. Verbal memory, negative symptomatology and prediction of psychosocial functioning in schizophrenia. Psychiatry Res. 2008;158(1):11-17.
12. Rocca P, Montemagni C, Zappia S, Pitera R, Sigaudo M, Bogetto F. Negative symptoms and everyday functioning in schizophrenia: a cross-sectional study in a real world-setting. Psychiatry Res. 2014;218(3):284-289.
13. Racenstein JM, Harrow M, Reed R, Martin E, Herbener E, Penn DL. The relationship between positive symptoms and instrumental work functioning in schizophrenia: a 10 year follow-up study. Schizophr Res. 2002;56(1-2):95-103.
14. Perivoliotis D, Granholm E, Patterson TL. Psychosocial functioning on the Independent Living Skills Survey in older outpatients with schizophrenia. Schizophr Res. 2004;69(2-3):307-316.
15. Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res. 2009;113(2-3):189-199.
16. Mausbach BT, Moore R, Bowie C, Cardenas V, Patterson TL. A review of instruments for measuring functional recovery in those diagnosed with psychosis. Schizophr Bull. 2009;35(2):307-318.
17. Thavichachart N, Kongsakon R, Lo WT, et al. The psychopathological characteristics of treatment discontinuation group in 6-month treatment with paliperidone ER. Int J Clin Pract. 2012;66(10):969-975.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington (DC): American Psychiatric Association; 1994.
19. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101:323-329.
20. Srisurapanont M, Arunpongpaisal S, Chuntaruchikapong S, et al. Cross-cultural validation and inter-rater reliability of the Personal and Social Performance scale, Thai version. J Med Assoc Thai. 2008;91(10):1603-1608.
21. Guy W. Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): US Department of Health, Education, and Welfare; 1976.
22. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
23. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988;23(1):99-110.
24. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997; 58(12):538-546.
25. Patrick DL, Burns T, Morosini P, et al. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr Med Res Opin. 2009;25(2):325-338.
26. Alptekin K, Erkoc S, Gogus AK, et al. Disability in schizophrenia: clinical correlates and prediction over 1-year follow-up. Psychiatry Res. 2005;135(2):103-111.
27. Gorna K, Jaracz K, Rybakowski F, Rybakowski J. Determinants of objective and subjective quality of life in first-time-admission schizophrenic patients in Poland: a longitudinal study. Qual Life Res. 2008;17(2):237-247.
28. Thirthalli J, Venkatesh BK, Kishorekumar KV, et al. Prospective comparison of course of disability in antipsychotic-treated and untreated schizophrenia patients. Acta Psychiatr Scand. 2009;119(3):209-217.
29. Kurtz MM. Symptoms versus neurocognitive skills as correlates of everyday functioning in severe mental illness. Expert Rev Neurother. 2006;6(1):47-56.
30. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162(3):495-506.
31. Shamsi S, Lau A, Lencz T, et al. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res. 2011;126(1-3):257-264.
32. Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. Schizophr Res. 2012;137(1-3):147-150.
33. Carlsson R, Nyman H, Ganse G, Cullberg J. Neuropsychological functions predict 1-and 3-year outcome in first-episode psychosis. Acta Psychiatr Scand. 2006;113(2):102-111.
34. Howanitz E, Cicalese C, Harvey PD. Verbal fluency and psychiatric symptoms in geriatric schizophrenia. Schizophr Res. 2000;42(3):167-169.
35. Addington J, Addington D. Premorbid functioning, cognitive functioning, symptoms and outcome in schizophrenia. J Psychiatry Neurosci. 1993;18(1):18-23.
36. Velligan DI, Mahurin RK, Diamond PL, Hazleton BC, Eckert SL, Miller AL. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res. 1997;25(1):21-31.
37. Hofer A, Baumgartner S, Edlinger M, et al. Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects. Eur Psychiatry. 2005;20(5-6):386-394.
38. Novick D, Haro JM, Suarez D, Vieta E, Naber D. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 2009;108(1-3):223-230.
39. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry. 1991;48(3):239-246.
40. Lincoln TM, Hodgins S. Is lack of insight associated with physically aggressive behavior among people with schizophrenia living in the community? J Nerv Ment Dis. 2008;196(1):62-66.
41. Dickerson F, Boronow JJ, Ringel N, Parente F. Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up. Schizophr Res. 1999;37(1):13-20.
42. Friedman JI, Harvey PD, Coleman T, et al. Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer’s disease and normal aging. Am J Psychiatry. 2001;158(9):1441-1448.
43. Suttajit S, Punpuing S, Jirapramukpitak T, et al. Impairment, disability, social support and depression among older parents in rural Thailand. Psychol Med. 2010;40(10):1711-1721.
44. Kao YC, Liu YP. Effects of age of onset on clinical characteristics in schizophrenia spectrum disorders. BMC Psychiatry. 2010;10:63.
45. Ongur D, Lin L, Cohen BM. Clinical characteristics influencing age at onset in psychotic disorders. Compr Psychiatry. 2009;50(1):13-19.
46. Sham PC, Jones P, Russell A, et al. Age at onset, sex, and familial psychiatric morbidity in schizophrenia. Camberwell Collaborative Psychosis Study. Br J Psychiatry. 1994;165(4):466-473.
47. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005;79(2-3):231-238.
48. Bowie CR, Depp C, McGrath JA, et al. Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. Am J Psychiatry. 2010;167(9):1116-1124.
49. Bell M, Tsang HW, Greig TC, Bryson GJ. Neurocognition, social cognition, perceived social discomfort, and vocational outcomes in schizophrenia. Schizophr Bull. 2009;35(4):738-747.